Reports - Anticoccidial Drugs Market
Anticoccidial Drugs Market Size, Share & Trends Analysis Report by Drug Class (Ionophore, Synthetic Drugs) by Drug Action (Coccidiostatic, Coccidiocidal) by Animal (Livestock Animals, Companion Animals) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Industry Assessment (2018 - 2023) & Forecast (2024 - 2032)
Industry Leaders Trust Us For Actionable Intelligence
2035
4.55%
North America
Asia Pacific
2019 - 2023
2023 - 2035
The final deliverable will encompass both quantitative and qualitative data, providing a comprehensive analysis of the market. The scope is customizable.
The global Anticoccidial Drugs Market is valued at USD 192.5 Million in 2023 and is projected to reach a value of USD 313.8 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 4.55% between 2024 and 2032.
{{bar_graph}}
With a revenue share of 43.2% in 2023, the North American region contributed the most to the markets growth and is predicted to continue leading the way. This is due to factors such as the increasing trend of animal adoption and higher spending on animal healthcare within the region. North America is a major player in the worldwide meat, dairy, and egg sectors, accounting for about 80 billion animal slaughters per year. 98% of all animals utilized by humans in various industries are those reared for food, according to the FAO. The data shows that acute diarrhea is not the leading cause of diagnosed cases in beef and dairy calves but relatively high coccidial oocyst counts. This highlights the urgent need for effective solutions in the North American livestock industry. The need to address coccidiosis issues arises from North Americas continued leadership in animal husbandry worldwide.
The U.S. Anticoccidial Drugs Market is valued at USD 48.57 Million in 2023 and is projected to reach a value of USD 67.10 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 3.7% between 2024 and 2032. The United States Anticoccidial Drugs Market is accounted for significant growth, primarily driven by the nationwide surge in trend of pet adoption. According to the recent findings from the 2023-2024 American Pet Products Association (APPA) National Pet Owners Survey, 66% of U.S. households, totalling 86.9 million, own pets. This includes 65.1 million households with dogs, 46.5 million with cats, and 2.2 million with horses. The surge in the adoption of companion animals, which are inherently more susceptible to fungal diseases like coccidiosis, is anticipated to fuel the demand for Anticoccidial Drugs in the foreseeable future.
The global Anticoccidial Drugs market can be categorized as Drug Class, Drug Action, Animal, and Region.
In 2023, the synthetic Drugs segment led the market and accounted for a revenue share of 80.4%. Based on Drug Class, the Anticoccidial Drugs market is divided into Ionophore and Synthetic Drugs. Synthetic drugs offer several advantages over other types of anticoccidials. They are chemically synthesized compounds specifically designed to target and kill coccidian parasites. This targeted approach ensures high efficacy and specificity, reducing the risk of resistance development. Synthetic medications are useful for commercial chicken production because they facilitate easy administration and accurate dosage. Additionally, the creation of novel synthetic medications with enhanced effectiveness and less adverse effects has further fuelled this markets expansion. Pharmaceutical companies invest in research and development to create novel compounds with superior antiparasitic properties. These advancements have facilitated the availability of a wide range of synthetic drugs in the market, providing poultry producers with more options for disease control.
The Coccidiostatic segment accounted for the most significant revenue share of 78.2% in 2023. By Drug Action, the Anticoccidial Drugs market is classified into Coccidiostatic and Coccidiocidal. The poultry industry has grown as a result of consumer demand for chicken goods including meat and eggs. As coccidiosis is a significant threat to poultry production, there is a growing need for effective prevention and control measures, including coccidiostats. Additionally, the surge in the cattle business can be attributed to the growing world population and the consequent demand for food sources that are rich in protein. As a result, there is a greater focus on improving the productivity and efficiency of livestock operations, including preventing and controlling diseases like coccidiosis. Coccidiostats are essential for accomplishing these objectives since they minimize the losses brought on by coccidiosis while also enhancing the general well-being and productivity of the animals.
The companion animals segment accounted for the significant growth of the market with revenue share of 58.4%. Based on Animal, the Anticoccidial Drugs market is classified into Livestock Animals (Cattle, Poultry, Other Livestock Animals) and Companion Animals (Dogs, Cats, Other Companion Animals). There has been a significant increase in pet ownership worldwide. People are increasingly looking to own pets, such as dogs and cats, for companionship and emotional support. This rise in pet ownership has led to increased demand for veterinary services, including treating parasitic infections like coccidiosis. As a result, the demand for Anticoccidial Drugs for companion animals has also improved. In addition, there has been a progressive shift in pet owners' mindset towards healthcare and preventive measures for their pets. Nowadays, more and more pet owners are aware of the different illnesses and infections, including coccidiosis, that can afflict their animals. They are more willing to invest in preventive measures and treatments to ensure the health and well-being of their pets. This has increased sales and consumption of Anticoccidial Drugs in the companion animal market.
As per the 2023–2024 APPA National Pet Owners Survey, 86.9 million households in the United States are home to 66% of pets. The most common pets are dogs, owned by 65.1 million households, followed by cats (46.5 million households) and freshwater fish (11.1 million households). Small animals (6.7 million homes), reptiles (6.0 million households), saltwater fish (2.2 million households), birds (6.1 million households), and horses (2.2 million households) are some of the other common pet species. This diverse range of pet ownership, coupled with an analysis of pet ownership trends across generations, highlights the potential of the Anticoccidial Drugs Market. Generation Z, comprising 16% of current pet owners, is paving the way for Millennials, who constitute 33% of pet owners. Baby Boomers make up 24% of the contribution, followed closely by Generation X at 25%, and the Builders at 2%. The strong bond between households and their pets indicates a high demand for Anticoccidial Drugs, emphasizing the need for innovative solutions to protect the health and well-being of these beloved animal companions.
{{dashboard_image}}
Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point
Dynamic Pet Ownership Patterns and Rising Global Awareness Navigate the Boom in Anticoccidial Drugs Market Growth
The Anticoccidial Drugs Market is set to grow significantly due to the changing dynamics of pet ownership among different generations. An in-depth analysis shows that Millennials are the most extensive pet owners, accounting for 33% of the current pet population. Generation X and Baby Boomers also have a significant presence in the market, with 25% and 24%, respectively. Generation Z comprises 16% of pet owners, while Builders represent 2%. This strong connection between households and their pets creates a steady demand for Anticoccidial Drugs, as people want to ensure the health and well-being of their beloved animals. The trend of increasing companion animal ownership is not limited to the United States; Canada and Mexico are also experiencing growth. According to recent Pet Keen data, 38% of Canadian households owned a cat, and 35% owned a dog in 2021, indicating a willingness to invest in pet healthcare. The frequency of coccidiosis in dogs and cats is also bringing attention from pet owners, which is anticipated to fuel demand for novel medications and support the markets overall expansion for anticoccidial pharmaceuticals.
Evolving Coccidiosis Challenges Thrives the Demand for Anticoccidial Drugs Market
The Anticoccidial Drugs Market is experiencing a high demand due to the widespread problem of coccidiosis, especially in farms with poor hygiene practices. Effective control tactics are necessary for coccidiosis, which is influenced by age, breed, health circumstances, and biosecurity measures. Biosecurity practices are essential in preventing and managing coccidiosis. There are nearly 20 different Eimeria species found in cattle feces worldwide, showing that this issue is widespread. Clinical infection usually starts at 1-2 months of age, with cecal coccidiosis being the most severe form, causing up to 50% of deaths in flocks. In 2023, there was a decrease in the occurrence of Eimeria acervulina in birds compared to the previous year, but there was a concerning five-fold increase in gross Eimeria tenella lesions. This complicated situation regarding coccidiosis highlights the need for innovative and targeted Anticoccidial Drugs to address the evolving challenges in the poultry industry.
Key players in the Anticoccidial Drugs Market are making strategic moves and innovative endeavours. For instance, in February 2021, Merck Animal Health demonstrated its commitment to advancing the industry by acquiring PrognostiX Poultry Limited, operating as Poultry Sense Ltd. This move shows Mercks interest in expanding its portfolio and emphasizes the importance of specialized environmental and health monitoring solutions for the poultry sector. Additionally, with about 90.5 million American families keeping pets, the demand for pet ownership is rising, creating a lucrative market for anticoccidial medications. In March 2021, Elanco Animal Health Inc. introduced two anticoccidial feed additives in Sri Lanka, showing the global expansion of their product offerings. Thanks to recent developments and strategic acquisitions, Merck Animal Health and Elanco Animal Health Inc. have emerged as leaders in the Anticoccidial Drugs market. They are poised to address changing market needs, promote innovation, and drive future market growth.
The key players in the global Anticoccidial Drugs market include - Bayer AG (Germany) among others.
Source: www.vantagemarketresearch.com
Parameter | Details | |
---|---|---|
Segment Covered |
| |
Regions & Countries Covered |
| |
Companies Covered |
| |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis | |
Pricing and purchase options | Avail of customized purchase options to meet your exact research needs. Explore purchase options |
Base Year
Historic Year
NaN - NaN
Forecast Year
NaN - NaN
Contact
Toll Free Number+1 (877) 462-2282